PCAS key Figures (2018)

€206.7

million


Consolidated net sales

7


Production sites

€23.2

million


EBITDA
Earnings before interest, taxes, depreciation and amortization

1069


Employees

PCAS sales
/ by geographic zone /

par region
  • 35%
    Europe
  • 28%
    France
  • 18%
    Asian Pacific
  • 16%
    North America
  • 3%
    Others

PCAS sales
/ by market /

Par marche
  • 43%
    Pharma Synthesis Exclusive & Pharma Chemicals
  • 20%
    Pharma Sythesis Generic APls
  • 17%
    Performance Fine Chemicals
  • 20%
    Advanced Specialties

Breakdown of PCAS
Share Capital at
12/31/2017

repartition capital
  • 76.14%
    Seqens (ex Novacap)
  • 8.08%
    Public
  • 8.18%
    Auto detention
  • 6.50%
    Inocap gestion*
  • 1.10%
    Management
In millions of euros20172018
Net sales218.3206.7
Pharmaceutical synthesis
Fine specialty chemicals
148.9
69.3
130.4
76.3
EBITDA*31.523.2
EBITDA margin14.4%11.2%
EBIT*19.19.9
EBIT margin8.8%4.8%
Other operating income and expenses
Financial result
Taxes
-5.2
-4.4
-3.8
-7.1
-3.5
-1.7
Net Income5.8-2.4
Equity
Net debt
103.5
56.7
95.6
56.9
Gearing0.550.61
Net asset attributable to the Group per share7.266.88

*Including research tax credit of €3.7 million in 2017 and €4.4 million 2018.

key figures

At February 20 2019

Code ISINFR 0000053514 - PCA
Number of actions15 141 725
Excluding self-detention13 902 858
CompartmentEuronext C Market
Share price13.70 euros
Market capitalization207.4 millions euros
Analyst coverageKepler Chevreux - Portzamparc and Midcap Partners

PCAS and the stock market

Key adjusted per share figures

In euros20172018
Highest price18.8120.00
Lowest price12.1111.88
Price at the end of December18.1213.10
Net sales14.4113.65
Current operating income1.260.66
Net profit attributable to the Group0.41-0.02

PCAS shares are listed on Nyse Euronext, compartment C. The shares have been continuously listed since October 17, 1996 and are subject to a liquidity contract with Kepler Cheuvreux.

PCAS 2018 share price


actions 2019

Contacts: